American society – Vet Clin Path Journal Wed, 02 Jun 2021 15:24:34 +0000 en-US hourly 1 American society – Vet Clin Path Journal 32 32 Budget targets Removal of lead pipes, repairs to water supply infrastructure, job creation Wed, 02 Jun 2021 15:03:30 +0000

Every day, tens of millions of Americans drink primarily from lead straws. They get their drinking water from lead water pipes in the ground which can threaten their health by contributing to high levels of lead in their families’ tap water. Tens of millions more are served by decrepit water supplies struggling to provide water that meets basic health and safety standards. And when people in cities and towns across the country flush their toilets, sewage often goes untreated in rivers and lakes during storms due to insufficient sewers and water plants. treatment. Others have no sanitation at all, are left on “straight pipes” that bring their raw waste directly into a nearby stream, or still use backyard latrines.

Now is the time to invest in fixing our long overlooked hydraulic infrastructure defects that prompted the American Society of Civil Engineers to classify our drinking water systems to a “C-” and storm water systems to a “D.” It’s a newsletter that we would be ashamed to bring back to mom and dad.

The president’s budget for fiscal year 2022 (FY22) would be a down payment to deal with this crisis. It would invest $ 3.6 billion in hydraulic infrastructure. This would represent a modest but significant increase from the current fiscal year of roughly $ 2.8 billion invested in EPA water infrastructure funding.

Ultimately, it will take a lot more clearly. The US presidential plan for jobs would invest $ 45 billion to remove all lead pipes in the country from the ground, as well as significant additional investments in repairing our water infrastructure, for a total of $ 111 billion.

Investment in hydraulic infrastructure will be a big creator of jobs. For example, a recent study by the Metropolitan Planning Council found that replacing all of Illinois’ lead service lines alone could create up to 224,500 jobs and $ 23 billion in additional economic activity. Expand that to a national investment, and the number of new, well-paying jobs will be huge. Indeed, a University of Massachusetts study found that investing $ 35 billion per year in water infrastructure would create around 475,000 jobs. And most jobs in the water utility pay a good living wage; even at the lower end of the spectrum, a Brooking study found that jobs in the water industry pay up to 50 percent more than comparable jobs in other fields.

This investment will not only improve the protection of our water and create well-paying jobs, but it can and will address environmental injustices. The NRDC has learned from our partners in Flint, Newark, Pittsburgh and other cities, and from our reviews of EPA data, that those left behind by divestment in water infrastructure are communities of color to disproportionately low income. As shown in a study and map reproduced below developed by my colleague, Dr Kristi Pullen Fedinick, lead contamination is a national problem, but it is often more particularly concentrated in certain less wealthy communities.

Populations served by drinking water systems with 90th percentile lead samples greater than 1 part per billion

Kristi Pullen Fedinick (NRDC)

In addition to many urban communities that have suffered from severe disinvestment in their infrastructure, disadvantaged rural and tribal communities are also in serious danger. Families in these communities often have to live with severely contaminated water or no water at all on a daily basis, have lead service lines and sometimes have raw sewage flow in their streets or completely lack sanitation. In many of these communities, democracy itself has been seriously compromised. In Flint, for example, state-appointed officials made fateful reckless decisions that led to severe contamination, with residents and their elected officials effectively disenfranchised.

The time is long past for us to make the necessary investments to protect our health and our waterways. President Biden’s budget and the US Jobs Plan will take a big step towards making these essential investments.

Source link

]]> 0
Study Provides New Information on Risk of COVID-19 in Patients on Dialysis Tue, 01 Jun 2021 21:02:50 +0000

Strong points

  • Among people with kidney failure who received dialysis at clinics several times a week, the risks of COVID-19 were higher in older patients with diabetes living in local communities with COVID rates -19 higher and having received dialysis in clinics that served a greater number of patients.
  • Risks were lower in patients who received dialysis at clinics with a higher number of side chambers available and who had mask policies for asymptomatic patients.

Washington, DC (June 1, 2021) – Many people with kidney failure have been unable to self-isolate during the COVID-19 pandemic because they require dialysis treatments in clinics several times a week. New research that will appear in a future issue of CJASN highlights the risks run by these patients and the factors involved.

For the study, Ben Caplin, MBChB, PhD (University College London) and colleagues, on behalf of the Pan-London COVID-19 Renal Audit Group, reviewed information on 5,755 patients who received dialysis at 51 clinics in London. Between March 2 and May 31, 2020, a total of 990 (17%) patients tested positive and 465 (8%) were admitted to hospitals on suspicion of COVID-19. The risks of COVID-19 were higher in older patients with diabetes, living in local communities with higher rates of COVID-19, and who received dialysis at dialysis clinics that served a greater number of patients. Risks were lower in patients who received dialysis at clinics with a higher number of side chambers available and who had mask policies for asymptomatic patients. No independent association was observed with gender, ethnicity or deprivation measures.

“Taken together, the results confirm the high rates of symptomatic COVID-19 in patients receiving on-center dialysis and suggest sources of transmission both within the dialysis units and in the communities of origin of patients,” said Dr. Caplin. “The work also suggests that in addition to isolating confirmed cases, addressing factors that could reduce transmission from patients without suspected or confirmed disease could provide an additional opportunity to further modify the impact of COVID-19. in this population. ”


Study co-authors include Damien Ashby, Kieran McCafferty, Richard Hull, Elham Asgari, Martin L. Ford, Nicholas Cole, Marilina Antonelou, Sarah A. Blakey, Vinay Srinivasa, Dandisonba CB Braide-Azikwe, Tayeba Roper, Grace Clark, Helen Cronin, Nathan J. Hayes, Bethia Manson, Alexander Sarnowski, Richard Corbett, Kate Bramham, Eirini Lioudak7, Nicola Kumar, Andrew Frankel, David Makanjuola, Claire C. Sharpe, Debasish Banerjee and Alan D. Salama.

Disclosures: Dr Caplin reports Lifearc personal expenses, Astra Zeneca grants, Colt Foundation grants, Medical Research Council grants, Royal Free Charity, outside of submitted work; Dr Ashby reports personal costs for Fibrogen, outside of submitted work; Dr Corbett is the holder of a patent WO2017148836A1: “A device for vascular connections” issued; Dr Banerjee reports grants from AstraZeneca, grants from Kidney Research UK, personal fees from ViforPharma, outside of submitted work.

The article, titled “Risk of COVID-19 Disease, Dialysis Unit Attributes, and Infection Control Strategy Among London In-Center Hemodialysis Patients”, will appear online at http: // / June 1, 2021.

The contents of this article do not reflect the views or opinions of the American Society of Nephrology (ASN). Responsibility for the information and opinions expressed therein rests entirely with their author (s). ASN does not offer medical advice. All the content of ASN publications is provided for informational purposes only and is not intended to cover all the uses, directions, precautions, drug interactions or possible adverse effects. This content should not be used in a medical emergency or for the diagnosis or treatment of any medical condition. Please consult your doctor or other qualified health care provider if you have any questions about any medical condition or before taking any medication, changing your diet, or starting or stopping any treatment. Do not ignore or delay obtaining professional medical advice because of the information accessible via ASN. Call 911 or your doctor for all medical emergencies.

Since 1966, ASN has led the fight to prevent, treat and cure kidney disease throughout the world by training healthcare professionals and scientists, advancing research and innovation, communicating new knowledge and advocating for the highest quality patient care. ASN has more than 21,000 members representing 131 countries. For more information visit http: //

Warning: AAAS and EurekAlert! are not responsible for the accuracy of any press releases posted on EurekAlert! by contributing institutions or for the use of any information via the EurekAlert system.

Source link

]]> 0
Race, QAnon and the Rise of Escape | News, Sports, Jobs Tue, 01 Jun 2021 04:31:35 +0000

A day when the United States is reeling from another mass shooting in San Jose, California; we learn that our local state representative, Don Jones (right), has nothing better to do than introduce a bill to Ohio House, which he says “Protects children from having to examine or be blamed for mistakes made in the past”. Really, what are Jones and his fellow Republicans afraid of now?

HB 322 actually says that humanities professors can no longer discuss the influence of race on political decisions as an issue in American history. This effort is a step backwards because it denies the fact that the implications of decisions made long ago continue to plague American society today. The bill targets the use of “Critical theory of race” by teachers at all educational institutions in Ohio.

As Republican lawmakers like Mr. Jones seek to ban discussion of race in our schools, a recent poll reports 20% of Americans actually believe far-right QAnon is conspiring Republican-promoted nonsense. Marjorie Taylor Greene, also a Republican. This groundless movement argues that the world is controlled by a “Cabal of pedophiles worshiping Satan” and that Donald Trump was sent to rid the world of progressives and therefore, “Satanic ideas”. Perhaps Mr. Jones and his Republican colleagues would prefer schools to teach QAnon theory. After all, when the facts don’t matter anymore; fantasy is a good way to escape reality.

While the question of QAnon and the denial of race as a historical influence do not appear to be related, they are in fact two sides of the same ill-advised coin. The saving fact is that 80% of Americans do NOT believe in the quackery theories of QAnon; however, removing the discussion of the importance of race, culture, and history in life today sets a dangerous precedent. Of course, history cannot be changed, but it must be looked at honestly. History can inform and educate future decision-makers and reassure minority groups of all stripes that their voices are heard. The way to resolve our divisions and move forward as a people is not to stop talking about real issues, but to face them with courage and honesty. Blame is not the point, empathy and understanding is the goal of both education and positive social change.

“Disappointed” is the best way to describe my reaction to the actions of Representative Jones. As a former educator, he should know better. Students today deserve to hear all facets of any issue, including the question of race; if not, we are entering another dark age where reason and truth are the first deaths. And after “Book engraving”?

Teresa R. Porter


Today’s breaking news and more delivered to your inbox

Source link

]]> 0
Arthur Muir and Tsang Yin-hung return unharmed after becoming America’s oldest woman and fastest on Everest Sun, 30 May 2021 17:00:22 +0000

KATHMANDU, Nepal – A retired Chicago lawyer who became the oldest American to climb Mount Everest, and a teacher from Hong Kong who is now the fastest climber to the world’s highest peak, returned Sunday in all safety of the mountain where the climbing teams struggled. with inclement weather and a coronavirus outbreak.

Arthur Muir, 75, peaked earlier this month, breaking the record set by fellow American Bill Burke at 67.

Tsang Yin-hung, 45, from Hong Kong, climbed the summit from base camp in 25 hours and 50 minutes and became the fastest climber. The 10 hour 56 minute record is held by a Sherpa guide, Lakpa Gelu.

A climbing accident on Everest in 2019, when Muir injured his ankle falling from a ladder, did not stop him from attempting to climb the summit again. He started mountaineering late in life and said he was scared and worried during his latest adventure.

“You realize how a mountain it is, how dangerous it is, how many things can go wrong. Yeah, it makes you nervous, it makes you feel some anxiety there and maybe a little bit. fear, ”Muir told reporters in Kathmandu. .

“I was just surprised when I got there (the top) but I was too tired to get up, and in my photos from the top I’m sitting,” he said.

Muir started mountaineering at 68 with trips to South America and Alaska before attempting Everest in 2019 when he fell off the ladder.

The escalation was closed last year due to the pandemic.

Married with three children, Muir has six grandchildren. The last – a boy – was born while still in the mountains during his current expedition.

Tsang made just two stops between base camp, located at 5,300 meters (17,390 feet), and the 8,849-meter (29,032 feet) summit for a change, and covered the near vertical distance in 25 hours and 50 minutes.

She was lucky because there were hardly any climbers on the way to the highest camp at Col Sud, after that on the way to the top she only encountered climbers making their descent, which did not slow down its rise in speed.

There are only a few days of good weather left on the mountain this year, with hundreds of climbers lining up to the top, many having to wait a long time in traffic jams on the highest trail.

“I just feel relieved and happy because I’m not looking to break a record,” she said. “I feel relieved because I can prove my work to my friends, to my students.”

She made a previous attempt on May 11, but bad weather forced her to turn around from a point very close to the summit. She then returned last Sunday.

“For the top it’s not just your ability, your teamwork, I think luck is very important,” she said.

A coronavirus outbreak among climbers and their guides at Everest base camp has forced at least three teams to cancel their expeditions. But hundreds more have tried to climb to the top, at a time when Nepal is on lockdown to fight its worst wave of COVID-19.

TREND: Video shows mouse eating meat at Columbus Circle Whole Foods

* Get information about eyewitnesses
* Follow us on youtube
* More local news
* Send us a news tip
* Download the abc7NY app for last minute alerts Submit a news tip

Copyright © 2021 by The Associated Press. All rights reserved.

Source link

]]> 0
Biogen’s Alzheimer’s drug is facing its moment of truth. Biotech investors are watching. Sat, 29 May 2021 00:38:00 +0000

Illustration by Elias Stein

Text size

Source link

]]> 0
Alkermes to Host Webcast with Panel of Oncology Experts to Discuss Nemvaleukin Alfa Data Presented at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting Fri, 28 May 2021 20:00:00 +0000

DUBLIN, May 28, 2021 / PRNewswire / – Alkermes plc (Nasdaq: ALKS) announced today that it will host a webcast and conference call at 4:00 p.m. ET (9:00 p.m. BST) at Friday June 4, 2021 to review data updates presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting of the Company’s ARTISTRY-1 and ARTISTRY-2 clinical trials evaluating the nemvaleukin alfa (nemvaleukin) candidate for immuno- oncology. The company will provide an overview of the data presented, followed by a panel discussion with expert oncologists and researchers from the ARTISTRY clinical program, Valentina boni, MD, Ph.D., medical oncologist and principal investigator, START Madrid at the Centro Integral Oncológico Clara Campal; and Omid Hamid, MD, chief of research and immunotherapy, The Angeles Clinic and Research Institute.

Investor and analyst webcast with expert oncologists
Date and time: Friday, June 4, 2021 at 4 p.m. ET (9:00 p.m. BST)
Compose: +1 877-407-2988 for US callers and +1 201-389-0923 for international callers.
Investors and analysts can also view slides and listen to the live audio webcast of the presentation on the Investors section of the Alkermes website at A replay of the webcast will be archived on the company’s website for 30 days after the presentation.

Nemvaleukin poster presentations at ASCO

Abstract: 2513
Title: ARTISTRY-1: Nemvaleukin Alfa as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors
Presenter: Valentina boni, MD, Ph.D., medical oncologist and principal investigator, START Madrid at the Centro Integral Oncológico Clara Campal, Madrid, Spain
Date / time of presentation: The on-demand poster discussion session will take place on June 4, 2021 at 9:00 a.m.ET.

Abstract: 2552
Title: Selection of the recommended phase 2 dose (RP2D) for subcutaneous nemvaleukin alfa: ARTISTRY-2
Presenter: Omid Hamid, MD, Head of Research and Immuno-Oncology, The Angeles Clinic and Research Institute
Date of presentation: The poster presentation will be available on request for participants from June 4, 2021.

About Nemvaleukin alfa (“nemvaleukin”)
Nemvaleukin is an innovative and experimental fusion protein composed of modified interleukin-2 (IL-2) and the high-affinity IL-2 alpha receptor chain, designed to selectively expand tumor-killing immune cells while simultaneously avoiding the activation of immunosuppressive cells by preferring binding to the IL-2 receptor complex of intermediate affinity. The selectivity of nemvaleukin is designed to take advantage of the proven anti-tumor effects of existing IL-2 therapy while alleviating some limitations.

About the ARTISTRY Clinical Development Program
ARTISTRY is an Alkermes sponsored clinical development program evaluating nemvaleukin alfa as a potential cancer immunotherapy. The ARTISTRY program includes multiple clinical trials evaluating intravenous and subcutaneous administration of nemvaleukin, both as monotherapy and in combination with anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with advanced solid tumors. Ongoing trials include: ARTIST-1, ARTIST-2, ARTIST-3 and ARTIST-6.

About Alkermes plc
Alkermes plc is a fully integrated global biopharmaceutical company developing innovative drugs in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on addiction and schizophrenia, as well as a pipeline of product candidates in development for schizophrenia, bipolar I disorder, neurodegenerative disorders and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes’ website at

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

Alkermes contacts:
For investors: Sandy Coombs, +1 781 609 6377
For media: Sourojit Bhowmick, Ph.D. +1 781 609 6397

SOURCE Alkermes plc

Related links

Source link

]]> 0
Researchers Create Machine Learning Model to Predict Dialysis Treatment or Inpatient Death COVID-19 Fri, 28 May 2021 04:02:25 +0000

Title of the paper: Approaches to predicting the need for acute dialysis and death in COVID-19

Journal: The American Society of Nephrology Clinical Journal (published online May 24, 2021)

Authors: Girish Nadkarni, MD, Associate Professor in the Department of Medicine (Nephrology), Clinical Director of the Hasso Plattner Institute for Digital Health, and Co-chair of the Mount Sinai Clinical Intelligence Center at the Icahn School of Medicine at Mount Sinai; Lili Chan, MD, assistant professor in the Department of Medicine (Nephrology) at Icahn School of Medicine at Mount Sinai; Akhil Vaid, MD, postdoctoral researcher in the Department of Genetics and Genomic Sciences, Icahn School of Medicine, Mount Sinai, and member of the Mount Sinai Clinical Intelligence Center and the Hasso Plattner Institute for Digital Health of Mount Sinai; and other co-authors.

Bottom Line: SARS-CoV-2, the virus that causes COVID-19, has infected more than 103 million people worldwide. Acute kidney injury (AKI) treated with dialysis was a common complication in patients hospitalized with COVID-19. Acute kidney injury is associated with increased risk of morbidity and mortality. Early prediction of which patients will need dialysis or who will suffer from a serious illness resulting in death during hospital care can improve appropriate monitoring and better inform conversations with patients and their caregivers.

Results: The Mount Sinai team developed and tested five different algorithms to predict patients requiring dialysis treatment or severe illness resulting in death on Days 1, 3, 5, and 7 of the hospital stay, using the data from the first 12 hours of admission to hospital. the health system of Mount Sinai. Of the five models, the XGBoost without an imputation method outperformed all others with higher precision and recall.

Why the research is interesting: While the Mount Sinai model requires further external review, such machine learning models can potentially be deployed across healthcare systems to help determine which COVID-19 patients are most at risk. risk of adverse effects from coronavirus. Early detection of patients at risk can improve closer monitoring of patients and spark earlier discussions about goals of care.

Who: More than 6,000 adults with COVID-19 admitted to five hospitals in the Mount Sinai health system.

When: COVID-19 patients admitted from March 10 to December 26, 2020.

What: The study uses a machine learning model to determine which COVID-19 patients are most at risk for treatment requiring dialysis or severe illness resulting in death.

How: The team used data from adults hospitalized with COVID-19 across the Mount Sinai health system to develop and validate five models for predicting dialysis treatment or death at different time periods – 1, 3, 5 and 7 days – after hospital admission. Patients admitted to Manhattan’s Mount Sinai Hospital were used for internal validation, while the other four hospital sites were part of the external validation cohort. Characteristics assessed included demographics, comorbidities, laboratory results, and vital signs within 12 hours of hospital admission.

The five models created and tested were: logistic regression, LASSO, random forest, and XGBoost with and without imputation. Of the total model approaches used, XGBoost without imputation had the largest area under the receiver curve and the area under the precision recall curve during internal validation for all time points. This model also had the highest test settings on external validation over all time windows. Characteristics such as red blood cell distribution width, creatinine, and blood urea nitrogen were the main drivers of the model’s prediction.

Study conclusions: Mount Sinai researchers developed and validated a machine learning model to identify COVID-19 hospital patients at risk for acute kidney injury and death. The non-imputation XGBoost model had the best performance compared to standard models and other machine learning models. The widespread use of electronic health records makes it possible to deploy prediction models like this one.

According to Dr Girish Nadkarni of Mount Sinai, on the research: The near universal use of electronic health records has created a huge amount of data, which has allowed us to generate prediction models that can directly aid in the patient care. A version of this model is currently being deployed at Mount Sinai Hospital in patients admitted with COVID-19.

Dr Lili Chan from Mount Sinai, on the research, said: As a nephrologist, we were overwhelmed by the increase in the number of AKI patients during the initial outbreak of the COVID-19 pandemic . Prediction models like this allow us to identify, from the start of the hospital journey, people at risk of severe ARI (those requiring dialysis) and death. This information will facilitate the clinical care of patients and inform discussions with patients and their families.

Dr Akhil Vaid of Mount Sinai said of the research: Machine learning allows us to discern complex patterns in large amounts of data. For COVID-19 hospital patients, this means being able to more easily identify new patients at risk, while also identifying the underlying factors that make them better or worse. The underlying algorithm, XGBoost, excels in accuracy, speed, and other features under the hood that allow easier deployment and understanding of model predictions.


To request a full copy of the paper or to schedule an interview with the research team, please contact the Mount Sinai Press Office at or 347-346-3390.

Warning: AAAS and EurekAlert! are not responsible for the accuracy of any press releases posted on EurekAlert! by contributing institutions or for the use of any information via the EurekAlert system.

Source link

]]> 0
North American Dogs Unintentionally Consume More Cannabis: Study Thu, 27 May 2021 11:36:32 +0000

The researchers hope that increased awareness of the problem will help the public take action.

Content of the article

The research team studied data from calls to the American Society for the Prevention of Cruelty to Animals (ASPCA) Poison Animal Control Center (APCC) via the veterinary database AnTox, which “stores clinical data. Comprehensive on animal toxicology related to these calls, identifies characterizes the toxic effects of substances in animals, ”according to reports from veterinarians and animal owners.

While cannabis use is rarely fatal for dogs, even when consuming small amounts of the drug – whether through inhaling or, more commonly, eating it – the results can still be extremely serious. Dogs can experience symptoms such as loss of balance, urinary incontinence, vomiting, breathing problems, seizures, tremors, or even a coma. Symptoms may appear for up to 12 hours after ingestion and in some cases last for several days.

Although the results are based on US data, clinicians say the results reflect the situation in Canada as well.

“We have evidence that dogs were exposed to cannabis more frequently throughout the study,” explains Howard-Azzeh. “If there is more cannabis in the environment, there are more opportunities for dogs to eat it.”

The researchers hope that increased awareness of the problem will help the public take action.

“We hope this study raises awareness of the potentially harmful effect of cannabis on dogs and highlights the need for people to better protect these types of products from vulnerable populations,” said Howard-Azzeh

  • Transfer cannabis products to paw and muzzle-proof containers, such as glass jars with secure, twist-off lids as soon as you bring them home. This has the added benefit of keeping your produce fresher.
  • Keep your stash within easy reach of your dog. A large wardrobe or closet are good options. “Dogs are not very discriminating in what they eat and are known to snatch food from kitchen counters and bedside tables, as well as to eat things on the floor or the floor,” Howard-Azzeh notes. .
  • Don’t throw your cockroaches on the ground. Make sure you properly dispose of leftover stems, joint ends, and other trash where your dogs (and others) won’t be curious and tempted to taste. Empty the ashtrays quickly after use. Keep a tight-fitting lid on the trash can.
  • Do not smoke in a confined space with your dog. Dogs can be affected by secondhand smoke.
  • If you suspect your dog has consumed cannabis products, contact your veterinarian immediately.

Content of the article

We apologize, but this video failed to load.

To subscribe to Weekend dispensary, a new weekly newsletter from The GrowthOp.

Source link

]]> 0
Troy Receives American Society for Nutrition Volunteer of the Year Award | News and Media Relations Office Wed, 26 May 2021 18:21:24 +0000

the American Society for Nutrition (ASN) and the ASN Foundation have selected Lisa M. Troy, Associate Professor of Nutrition, as the recipient of their ASN Volunteer of the Year award.

The Volunteer of the Year award rewards exceptional contributions to enhance, promote and support ASN’s activities and programs, and is awarded to Troy and his colleagues on the Minority Affairs and Diversity Committee. She will be virtually honored along with other ASN 2020 and 2021 award winners before and during the NUTRITION 2021 LIVE ONLINE event which will be held June 7-10.

“Creating a welcoming culture that encourages the participation of diverse people is a personal mission,” says Troy. “Such a culture strengthens our individual and collective contributions to science and, above all, our impact on public health. ASN is leading the way within the nutrition community on diversity through discourse and action. It has been an honor to be part of this effort – discussing thorny issues, generating creative solutions and embedding diversity into the fabric of an international scientific society.

ASN is the professional organization par excellence dedicated to a healthier world thanks to evidence-based nutrition. Founded in 1928, the company brings together researchers, medical practitioners, policy makers and industry leaders from around the world to expand the knowledge and applications of nutrition.

Consult the complete list of ASN award winners on the ASN website.

Source link

]]> 0
Irritable Bowel Syndrome in South and Central America Tue, 25 May 2021 09:43:19 +0000

New York, May 25, 2021 (GLOBE NEWSWIRE) – Announces the Release of the “South and Central America Irritable Bowel Syndrome Diagnostics Market Forecast to 2028 – Impact of COVID-19 and Regional Analysis by diagnosis and indication “-
2% from 2021 to 2028. Market growth is determined owing to some of the major driving factors such as the increasing prevalence of Irritable Bowel Syndrome and associated conditions and advancements in the diagnosis of the syndrome. On the other hand, the challenges in diagnosing IBS are likely to restrain the growth of the market during the forecast years.

Irritable Bowel Syndrome is a chronic gastrointestinal condition caused by disturbed bowel habits and abdominal pain. All over the world, people are witnessing a huge incidence of irritable bowel syndrome.

Some factors such as food allergies, developmental stages of gastroenteritis, sporadic movements of the colon, abnormal composition of serotonin in the colon, and mild celiac disease are some of the risk factors that cause colon syndrome. irritable. According to statistics from IBS Global Impact Report, in 2016, Latin America had an estimated prevalence rate of IBS of 17.5%. Such a staggering prevalence of Irritable Bowel Syndrome is likely to drive the Irritable Bowel Syndrome (IBS) diagnostics market over the forecast period. To combat irritable bowel syndrome, companies involved in the development of irritable bowel syndrome drugs are taking constructive steps to create awareness programs with the aim of raising awareness. Such initiatives are expected to drive the growth of the Irritable Bowel Syndrome (IBS) diagnostics market. In addition, the increasing number of FDA approvals and diagnostic development activities is likely to accelerate the growth of Irritable Bowel Syndrome (IBS) diagnostics market during the forecast period.

With the spread of the COVID-19 pandemic, it is discovered that a significant number of people across the world are suffering from Irritable Bowel Syndrome (IBS), as the COVID-19 pandemic has affected the psychological health of people, causing a higher level of stress can exaggerate the symptoms of irritable bowel syndrome (IBS).

Thus, the impact of COVID-19 is so far considered positive on the market. Hence, the increasing demand for Irritable Bowel Syndrome (IBS) diagnostics in South America and Central America is likely to drive the growth of Irritable Bowel Syndrome (IBS) diagnostics market.

On the basis of the diagnosis, the South and Central America Irritable Bowel Syndrome (IBS) Diagnosis market has been segmented into Laboratory Tests and Imaging Tests. In 2020, the laboratory testing segment held a larger share of the market and is expected to grow at a faster rate over the next few years.

On the basis of indication, South and Central America Irritable Bowel Syndrome (IBS) Diagnostics market is segmented into Pain & Cramps, Diarrhea, Constipation & Constipation & Alternating Diarrhea. Pain and Cramps segment held the largest market share in 2020 and is expected to register the highest market CAGR during the forecast period.

Some of the primary and secondary sources associated with this South and Central America Irritable Bowel Syndrome (IBS) Diagnostics market report are American Society for Gastrointestinal Endoscopy (ASGE), Centers for Disease Control and Prevention (CDC) and the International Foundation for Gastrointestinal Disorders (IFFGD).
Read the full report:

About Reportlinker
ReportLinker is an award winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.



Source link

]]> 0